Blog | Page 70 of 2178 | Real Peptides®

Cagrilintide Long Term Studies — What Research Shows

Cagrilintide long term studies show sustained weight loss and glycemic control over 68 weeks with GLP-1/amylin dual agonism mechanisms.

Cagrilintide Comparative Studies — Research Insights

Cagrilintide comparative studies reveal dual-agonist synergies that outperform single GLP-1 therapies. See the mechanisms, clinical endpoints, and trial

Cagrilintide Safety Studies — Trial Data & Risk Profile

Cagrilintide safety studies show 25–30% nausea rates during titration, with dual-agonist trials demonstrating superior tolerability versus GLP-1

Cagrilintide Mechanism Studies — Dual Amylin Agonism

Cagrilintide mechanism studies reveal dual amylin receptor agonism that delays gastric emptying and reduces caloric intake — with 50-day half-life

Survodutide Study — Dual GIP/GLP-1 Trial Results

Survodutide study data shows 18.6% body weight reduction in 48 weeks through dual GIP/GLP-1 receptor activation — Phase 3 results exceed prior GLP-1-only

Top Survodutide Studies — Evidence That Shaped GLP-1

Phase 2 trial showed 12.5% body weight reduction at 48 weeks — survodutide targets GLP-1 and glucagon receptors with striking metabolic outcomes.

Survodutide Animal Research — Dual GLP-1/Glucagon Agonism

Survodutide animal research shows dual GLP-1/glucagon agonism reduces visceral fat by 46–52% in obese rodent models and improves insulin sensitivity

Survodutide In Vitro Research — Mechanisms & Findings

Survodutide in vitro research shows dual GLP-1/glucagon agonism improves hepatic lipid metabolism and β-cell function — here’s what lab models reveal

Survodutide Pharmacology Studies — Dual Agonist Mechanisms

Survodutide pharmacology studies reveal dual GLP-1/glucagon receptor agonism drives 15-20% weight reduction and metabolic improvements. Phase 3 data shows

Survodutide Dose Response Research — Clinical Findings

Survodutide dose response research shows dose-dependent weight loss and metabolic improvements with distinct tolerability thresholds across 2.4–9.6mg

Category: Blog